Compare KALV & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALV | LGIH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2014 | 2013 |
| Metric | KALV | LGIH |
|---|---|---|
| Price | $26.80 | $46.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | $32.60 | ★ $75.90 |
| AVG Volume (30 Days) | ★ 5.4M | 409.4K |
| Earning Date | 07-09-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $50,000,000.00 | ★ $1,705,504,000.00 |
| Revenue This Year | $185.42 | $2.32 |
| Revenue Next Year | $59.23 | $17.94 |
| P/E Ratio | ★ N/A | $515.78 |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $33.55 |
| 52 Week High | $26.85 | $69.42 |
| Indicator | KALV | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 55.32 |
| Support Level | $14.25 | $45.69 |
| Resistance Level | $26.85 | $49.51 |
| Average True Range (ATR) | 0.07 | 2.26 |
| MACD | -0.22 | -0.14 |
| Stochastic Oscillator | 71.05 | 75.68 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.